| Date | Time | Source | Headline | Symbol | Company |
| 07/11/2011 | 12:30PM | Zacks | Update on Amylin's Bydureon - Analyst Blog | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/08/2011 | 4:14PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/08/2011 | 9:02AM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/07/2011 | 7:07PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/07/2011 | 7:07PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/07/2011 | 7:06PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/07/2011 | 5:23PM | Business Wire | Exenatide tQT Study Showed No Prolongation of QT Interval | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/07/2011 | 5:17PM | PR Newswire (US) | Exenatide tQT Study Showed No Prolongation of QT Interval | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/07/2011 | 8:16AM | Marketwired | MannKind and Amylin Embrace the Future of Diabetes Treatment | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/06/2011 | 4:11PM | Dow Jones News | UPDATE: How Lilly's Diabetes-Drug Alliance With Amylin Deteriorated | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/06/2011 | 1:24PM | Dow Jones News | How Lilly's Diabetes-Drug Alliance With Amylin Deteriorated | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/05/2011 | 4:33PM | Edgar (US Regulatory) | Statement of Ownership (SC 13G) | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/01/2011 | 11:00AM | Zacks | NVO Presents Degludec Data - Analyst Blog | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 07/01/2011 | 10:30AM | Zacks | Encouraging Data Presented by ALKS - Analyst Blog | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/30/2011 | 9:45AM | Dow Jones News | 2nd UPDATE: Lilly Lays Out Plans To Weather Stormy Years Ahead | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/28/2011 | 11:15AM | Zacks | Novo Nordisk Presents Data - Analyst Blog | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/26/2011 | 9:03AM | Dow Jones News | Sanofi: New Diabetes Drug Shown To Work As Well As Byetta | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/24/2011 | 7:46PM | Dow Jones News | Amylin, MannKind Shares Rise On Diabetes Data Releases | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/24/2011 | 5:05PM | Business Wire | Analysis Shows BYDUREON™ Was Not Associated with Clinically Relevant QT Prolongation in Patients with Type 2 Diabetes: Resu... | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/24/2011 | 5:05PM | Business Wire | Studies Show Effect of BYDUREON™ on A1C and Weight for Up to Three Years | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/24/2011 | 5:05PM | Business Wire | Once-Monthly Exenatide Improved Glucose Control in Patients with Type 2 Diabetes: Phase 2 Study Results Presented at ADA 2011 | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/24/2011 | 5:00PM | PR Newswire (US) | Studies Show Effect of BYDUREON™ on A1C and Weight for Up to Three Years | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/24/2011 | 5:00PM | PR Newswire (US) | Analysis Provides New Insights Into Use of SYMLIN® in Patients With Type 1 Diabetes Using Insulin Pumps | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/24/2011 | 5:00PM | PR Newswire (US) | Analysis Shows BYDUREON™ Was Not Associated with Clinically Relevant QT Prolongation in Patients with Type 2 Diabetes: Resu... | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/24/2011 | 5:00PM | PR Newswire (US) | Analysis Finds BYETTA® Associated with Lower Likelihood of Heart Failure Compared with Other Diabetes Therapies: Results Pre... | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/24/2011 | 5:00PM | PR Newswire (US) | Once-Monthly Exenatide Improved Glucose Control in Patients with Type 2 Diabetes: Phase 2 Study Results Presented at ADA 2011 | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/23/2011 | 1:12PM | Zacks | Alkermes Evenly Poised - Analyst Blog | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/23/2011 | 1:12PM | Zacks | Alkermes Evenly Poised - Analyst Blog | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/22/2011 | 12:39PM | Zacks | Bydureon Gains EU Approval - Analyst Blog | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |
| 06/22/2011 | 12:39PM | Zacks | Bydureon Gains EU Approval - Analyst Blog | NASDAQ:AMLN | Amylin Pharmaceuticals, Inc. (MM) |